Products - Renal cancer | Topic | NICE

Showing 43 products

Date | Title

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 April 2024
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 January 2023
Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 April 2022
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 March 2022
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 September 2020
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 September 2020
Cabozantinib for untreated advanced renal cell carcinoma (TA542)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 October 2018
Tivozanib for treating advanced renal cell carcinoma (TA512)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 March 2018
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 January 2018
Immunosuppressive therapy for kidney transplant in adults (TA481)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 October 2017
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 August 2017
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 February 2017
Nivolumab for previously treated advanced renal cell carcinoma (TA417)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 November 2016
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 February 2015
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 August 2013
Published:
23 February 2011
Irreversible electroporation for treating renal cancer (IPG443)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 February 2013
Single-port laparoscopic nephrectomy (IPG414)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
23 November 2011
Laparoscopic cryotherapy for renal cancer (IPG405)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 August 2011
Percutaneous cryotherapy for renal cancer (IPG402)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 July 2011
Percutaneous radiofrequency ablation for renal cancer (IPG353)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
28 July 2010
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 August 2009
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 March 2009
Laparoscopic partial nephrectomy (IPG151)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 January 2006
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 August 2005
Laparoscopic live donor simple nephrectomy (IPG57)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 May 2004
Improving outcomes in urological cancers (CSG2)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
19 September 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 October 2022
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
TBC
Nivolumab for adjuvant treatment of localised renal cell carcinoma [ID6362]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Kidney Cancer
Status:
In development
Expected publication date:
TBC
Subcutaneous nivolumab for treating advanced renal cell carcinoma after systemic treatment TSID 12008
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Symptomatic Breast Referral Resource Suite: Enhancing the Suspected Cancer Recognition and Referral Process
Product type:
Shared learning
Published:
10 November 2020
GatewayC: Improving early detection of cancer through e-learning for primary care
Product type:
Shared learning
Published:
31 January 2019
Overcoming the challenges of implementing the new NICE guidance for suspected cancer: recognition and referral
Product type:
Shared learning
Published:
8 January 2017